Lou Lange, MD, PhD, Executive Chairman and Founder

  • General Partner Asset Management; Senior Advisor to CEO, Gilead Sciences
  • Former Founder Chairman & CEO, CV Therapeutics; Chief of Cardiology and Professor of Medicine at Jewish Hospital Washington University

Adrienne MacMillan, Chief Financial Officer and Founder

  • Former CFO, Rapidscan Pharma Solutions; VP Finance, CVT

A Biopharmaceutical Company Focused on the Development and Commercialization of First-In-Class Drug Candidates for Addiction Disorders

ANS-6637 is Phase-2 Ready for Addiction Disorder Clinical Development

ANS-6637 is the first-in-class compound that utilizes a novel pathway for the treatment of substance and behavior based addictions. ANS-6637, a highly selective ALDH2 Inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine. In preclinical studies, ANS-6637 reduced alcohol, cocaine and opiate craving. Three Phase-1 clinical trials of ANS-6637 in 95 human subjects demonstrated pharmacokinetics and a safety profile that support initiating Phase-2 clinical trials.


Peter Strumph, President and Chief Executive Officer and Founder

  • Former SVP Operations, Portola Pharmaceuticals; CEO, Codexis; CEO, Nile Therapeutics; SVP Operations, CVT; Operations Planning, Biogen; Lieutenant, US Navy


Ivan Diamond, MD, PhD, Chief Science Officer and Founder

  • Senior Advisor, Gilead Sciences
  • Former VP Neurology Research, CVT;  Vice Chair, UCSF Department of Neurology; Founding Director, UCSF Ernest Gallo Clinic and Research Center

February 16, 2017 - Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences

​​GS-6637 utilizes a novel pathway for the potential treatment of substance and behavior based addictions